Wednesday, August 08, 2018 11:58 AM

EXPERT EMPHASIZES INCLUSIVITY IN PROSTATE CANCER TRIALS - ONCLIVE

Daniel J. George, MDAfrican-American men with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone acetate (Zytiga) plus prednisone in the Abi Race trial showed a longer median time to prostate-specific antigen (PSA) worsening than Caucasian patients.

Lead author Daniel J. George, MD, said that these results suggest that African-American men may experience greater benefit from chemotherapy and hormone-targeting treatment than Caucasians with mCRPC.

African-American patients are at a higher risk of developing and dying from prostate cancer, with an incidence rate of 60% in the United States, explained George. Additionally, these men are typically diagnosed later, which reflects the disparities in healthcare for African-American patients in general.

In the study, the rate of decline in PSA levels also was greater for African-American patients than for Caucasians at 82% versus 78%, respectively, for a greater than 30% decline; 74% versus 66%, greater than 50%; and 48% versus 38%, greater than 90%.

This is incredibly important; we need to recognize that African-American patients want to be part of clinical trials, said George. We need to write the studies for them to make a difference.

In an interview with OncLive, George, a medical oncologist at Duke Cancer Center, discussed the findings from Abi Race and the implications they ...

News source: GOOGLE NEWS

See also: Associated Urologists Nashville